Australian Hepatitis and Risk Survey in Prisons
- Conditions
- Hepatitis BHepatitis CHIV Infections
- Registration Number
- NCT05839522
- Lead Sponsor
- Kirby Institute
- Brief Summary
The Australian Hepatitis and risk survey in prisons (AusHep) is a national prison-based blood-borne virus (BBV) surveillance study. This biobehavioural survey involves point-of-care testing for hepatitis C (HCV) antibodies and RNA (if antibody positive), hepatitis B surface antigens, hepatitis B surface antibodies, and HIV surface antibodies, and an interview-style survey on prior testing and treatment history and engagement in risk behaviours. The study will recruit approximately 2400 prisoner participants from 25 representative prisons across Australia, annually.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 2400
- Any remandee or sentenced prisoner who has provided informed consent is eligible to participate in the study.
-
Individuals who are unable or unwilling to provide consent or abide by the requirements of the study, as assessed by the trained nurses. Some individuals may be considered unable to provide consent or abide by the requirements of the study if they are:
- Too mentally unwell to provide consent
- Profoundly intellectually impaired
- Unable to speak English and comprehend the survey.
Those excluded from participating in the study will be referred to the local prison clinic service for standard of care.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The prevalence of HCV in Australian prisons 1 Year This is estiamted by perfroming the HCV antibody test and HCV RNA viral load test on a representative prison population.
The prevalance of HBV in Australian prisons 1 year This is estimated by performing the HBV surface antigen test on a respresentative prison population
The prevalance of HIV in Australian prisons 1 year This is estimated by performing the HIV antibody test on a respresentative prison population.
- Secondary Outcome Measures
Name Time Method The factors associated with HCV and HBV infection investigated by the bio-behavioural survey. 1 Year The proportion of individuals who are engaged in each step of HBV and HCV care cascades 1 Year This is estimated by conducting the bio-behavioural survey.
The prevalence of risk behaviours and harm reduction access 1 Year The risk behavrious and harm reduction measures include injecting and non-injecting drug use, high risk injecting practices, sexual risk behaviours, tattooing; and bleach or opioid substitution therapy (OST) uptake. This is estimated by conducting the bio-behavioural survey.
The factors associated with engaging in each step of HCV and HBV care cascades and HBV vaccination investigated by the bio-behavioural survey. 1 Year
Trial Locations
- Locations (24)
Alexander Maconochie Centre
🇦🇺Hume, Australian Capital Territory, Australia
Bathurst Correctional Complex
🇦🇺Bathurst, New South Wales, Australia
John Morony Correctional Complex
🇦🇺Berkshire Park, New South Wales, Australia
Cessnock Correctional Centre
🇦🇺Cessnock, New South Wales, Australia
Mid North Coast Correctional Centre
🇦🇺Kempsey, New South Wales, Australia
South Coast Correctional Centre
🇦🇺Nowra, New South Wales, Australia
Silverwater Women's Correctional Centre
🇦🇺Silverwater, New South Wales, Australia
Wellington Correctional Centre
🇦🇺Wuuluman, New South Wales, Australia
Alice Springs Correctional Centre
🇦🇺Alice Springs, Northern Territory, Australia
Darwin Correctional Centre
🇦🇺Howard Springs, Northern Territory, Australia
Scroll for more (14 remaining)Alexander Maconochie Centre🇦🇺Hume, Australian Capital Territory, Australia